Literature DB >> 31558898

AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019.

Marc Thill1, Christian Jackisch2, Wolfgang Janni3, Volkmar Müller4, Ute-Susann Albert5, Ingo Bauerfeind6, Jens Blohmer7, Wilfried Budach8, Peter Dall9, Ingo Diel10, Peter A Fasching11, Tanja Fehm12, Michael Friedrich13, Bernd Gerber14, Volker Hanf15, Nadia Harbeck16, Jens Huober3, Cornelia Kolberg-Liedtke7, Hans-Heinrich Kreipe17, David Krug18, Thorsten Kühn19, Sherko Kümmel20, Sibylle Loibl21, Diana Lüftner22, Michael Patrick Lux23, Nicolai Maass24, Volker Möbus25, Markus Müller-Schimpfle26, Christoph Mundhenke24, Ulrike Nitz27, Kerstin Rhiem28, Achim Rody29, Marcus Schmidt30, Andreas Schneeweiss31, Florian Schütz32, Hans-Peter Sinn33, Christine Solbach34, Erich-Franz Solomayer35, Elmar Stickeler36, Christoph Thomssen37, Michael Untch38, Frederik Wenz39, Isabell Witzel4, Achim Wöckel39, Nina Ditsch16.   

Abstract

Every year the Breast Committee of the Arbeitsgemeinschaft Gynäkologische Onkologie (German Gynecological Oncology Group, AGO), a group of gynecological oncologists specialized in breast cancer and interdisciplinary members specialized in pathology, radiologic diagnostics, medical oncology, and radiation oncology, prepares and updates evidence-based recommendations for the diagnosis and treatment of patients with early and metastatic breast cancer. Every update is performed according to a documented rule-fixed algorithm, by thoroughly reviewing and scoring the recent publications for their scientific validity and clinical relevance. This current publication presents the 2019 update on the recommendations for metastatic breast cancer.

Entities:  

Keywords:  AGO grades of recommendation; Bone health; Early and metastatic breast cancer; Locoregional recurrence; Oxford level of evidence; Therapy

Year:  2019        PMID： 31558898      PMCID： PMC6751428          DOI： 10.1159/000500999

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


  11 in total

1.  Adjuvant Radiotherapy for Breast Cancer: More than Meets the Eye.

Authors:  David Krug
Journal:  Breast Care (Basel)       Date:  2020-04-15       Impact factor: 2.860

2.  Low-dose metronomic chemotherapy as an efficient treatment option in metastatic breast cancer-results of an exploratory case-control study.

Authors:  S Krajnak; C Schnatz; K Almstedt; W Brenner; F Haertner; A-S Heimes; A Lebrecht; G-M Makris; R Schwab; A Hasenburg; M Schmidt; M J Battista
Journal:  Breast Cancer Res Treat       Date:  2020-06-03       Impact factor: 4.872

Review 3.  PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer.

Authors:  Nicola Fusco; Umberto Malapelle; Matteo Fassan; Caterina Marchiò; Simonetta Buglioni; Simonetta Zupo; Carmen Criscitiello; Paolo Vigneri; Angelo Paolo Dei Tos; Eugenio Maiorano; Giuseppe Viale
Journal:  Front Oncol       Date:  2021-03-25       Impact factor: 6.244

4.  Targeting Solid Tumors With BTK Inhibitors.

Authors:  Fatih M Uckun; Taracad Venkatachalam
Journal:  Front Cell Dev Biol       Date:  2021-04-14

5.  Metastases-directed Radiotherapy in Addition to Standard Systemic Therapy in Patients with Oligometastatic Breast Cancer: Study protocol for a randomized controlled multi-national and multi-center clinical trial (OLIGOMA).

Authors:  David Krug; Reinhard Vonthein; Alicia Illen; Denise Olbrich; Jörg Barkhausen; Julia Richter; Wolfram Klapper; Claudia Schmalz; Achim Rody; Nicolai Maass; Dirk Bauerschlag; Nicole Heßler; Inke R König; Kathrin Dellas; Jürgen Dunst
Journal:  Clin Transl Radiat Oncol       Date:  2021-04-05

Review 6.  Long Noncoding RNAs Regulate the Radioresistance of Breast Cancer.

Authors:  Zhifeng Li; Fujin Wang; Yinxing Zhu; Ting Guo; Mei Lin
Journal:  Anal Cell Pathol (Amst)       Date:  2021-09-20       Impact factor: 2.916

7.  The Lack of Evidence for an Association between Cancer Biomarker Conversion Patterns and CTC-Status in Patients with Metastatic Breast Cancer.

Authors:  Stefan Stefanovic; Thomas M Deutsch; Sabine Riethdorf; Chiara Fischer; Andreas Hartkopf; Peter Sinn; Manuel Feisst; Klaus Pantel; Michael Golatta; Sara Y Brucker; Marc Sütterlin; Andreas Schneeweiss; Markus Wallwiener
Journal:  Int J Mol Sci       Date:  2020-03-21       Impact factor: 5.923

8.  Update Breast Cancer 2020 Part 3 - Early Breast Cancer.

Authors:  Jens Huober; Andreas Schneeweiss; Andreas D Hartkopf; Volkmar Müller; Michael P Lux; Wolfgang Janni; Johannes Ettl; Erik Belleville; Marc Thill; Peter A Fasching; Hans-Christian Kolberg; Carla E Schulmeyer; Manfred Welslau; Friedrich Overkamp; Hans Tesch; Tanja N Fehm; Diana Lüftner; Florian Schütz; Achim Wöckel
Journal:  Geburtshilfe Frauenheilkd       Date:  2020-11-06       Impact factor: 2.915

Review 9.  Shared decision making in breast cancer treatment guidelines: Development of a quality assessment tool and a systematic review.

Authors:  Marta Maes-Carballo; Isabel Muñoz-Núñez; Manuel Martín-Díaz; Luciano Mignini; Aurora Bueno-Cavanillas; Khalid Saeed Khan
Journal:  Health Expect       Date:  2020-08-03       Impact factor: 3.377

10.  Impact of guideline changes on adoption of hypofractionation and breast cancer patient characteristics in the randomized controlled HYPOSIB trial.

Authors:  David Krug; Reinhard Vonthein; Andreas Schreiber; Alexander D Boicev; Jörg Zimmer; Reinhold Laubach; Nicola Weidner; Stefan Dinges; Matthias Hipp; Ralf Schneider; Evelyn Weinstrauch; Thomas Martin; Juliane Hörner-Rieber; Denise Olbrich; Alicia Illen; Nicole Heßler; Inke R König; Kathrin Dellas; Jürgen Dunst
Journal:  Strahlenther Onkol       Date:  2020-12-15       Impact factor: 3.621
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.